<!DOCTYPE html> <html lang="en" class=""></html><html> <head> <meta name="google-site-verification" content=""> <meta charset="utf-8"> <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <title>Are There Groups of Crohn's Disease Patients with Similar Faecal Calprotectin Patterns Over Time? | Nathan Constantine-Cooke</title> <meta name="author" content="Nathan Constantine-Cooke"> <meta name="description" content="Postdoctoral research associate characterising heterogeneity in IBD using longitudinal biomarker profiles. "> <meta name="keywords" content="IBD Precision-medicine Research"> <meta property="og:site_name" content="Nathan Constantine-Cooke"> <meta property="og:type" content="website"> <meta property="og:title" content="Nathan Constantine-Cooke | Are There Groups of Crohn's Disease Patients with Similar Faecal Calprotectin Patterns Over Time?"> <meta property="og:url" content="https://www.constantine-cooke.com/blog/2023/lcmm-cgh/"> <meta property="og:description" content="Postdoctoral research associate characterising heterogeneity in IBD using longitudinal biomarker profiles. "> <meta property="og:image" content="favicon.png"> <meta property="og:locale" content="en"> <meta name="twitter:card" content="summary"> <meta name="twitter:title" content="Are There Groups of Crohn's Disease Patients with Similar Faecal Calprotectin Patterns Over Time?"> <meta name="twitter:description" content="Postdoctoral research associate characterising heterogeneity in IBD using longitudinal biomarker profiles. "> <meta name="twitter:image" content="favicon.png"> <meta name="twitter:site" content="@IBDNathan"> <meta name="twitter:creator" content="@IBDNathan"> <script defer type="application/ld+json">
      {
        "author":
        {
          "@type": "Person",
          "name": "Nathan  Constantine-Cooke"
        },
        "url": "https://www.constantine-cooke.com/blog/2023/lcmm-cgh/",
        "@type": "WebSite",
        "description": "Postdoctoral research associate characterising heterogeneity in IBD using longitudinal biomarker profiles. 
",
        "headline": "Are There Groups of Crohn's Disease Patients with Similar Faecal Calprotectin Patterns Over Time?",
        "sameAs": ["https://orcid.org/0000-0002-4437-8713", "https://scholar.google.com/citations?user=2emHWR0AAAAJ", "https://www.researchgate.net/profile/Nathan-Constantine-Cooke", "https://github.com/nathansam", "https://www.linkedin.com/in/nathan-constantine-cooke", "https://twitter.com/IBDNathan", "https://www.ed.ac.uk/profile/constantine-cooke"],
        "name": "Nathan  Constantine-Cooke",
        "@context": "https://schema.org"
      }
    </script> <link rel="apple-touch-icon" sizes="180x180" href="/apple-touch-icon.png"> <link rel="icon" type="image/png" sizes="32x32" href="/favicon-32x32.png"> <link rel="icon" type="image/png" sizes="16x16" href="/favicon-16x16.png"> <link rel="manifest" href="/site.webmanifest"> <link rel="mask-icon" href="/safari-pinned-tab.svg" color="#5bbad5"> <meta name="viewport" content="width=device-width, initial-scale=1"> <link href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.1/dist/css/bootstrap.min.css" rel="stylesheet" integrity="sha256-DF7Zhf293AJxJNTmh5zhoYYIMs2oXitRfBjY+9L//AY=" crossorigin="anonymous"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/mdbootstrap@4.20.0/css/mdb.min.css" integrity="sha256-jpjYvU3G3N6nrrBwXJoVEYI/0zw8htfFnhT9ljN3JJw=" crossorigin="anonymous"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@5.15.4/css/all.min.css" integrity="sha256-mUZM63G8m73Mcidfrv5E+Y61y7a12O5mW4ezU3bxqW4=" crossorigin="anonymous"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/academicons@1.9.1/css/academicons.min.css" integrity="sha256-i1+4qU2G2860dGGIOJscdC30s9beBXjFfzjWLjBRsBg=" crossorigin="anonymous"> <link rel="stylesheet" type="text/css" href="https://fonts.googleapis.com/css?family=Roboto:300,400,500,700|Roboto+Slab:100,300,400,500,700|Material+Icons"> <link rel="shortcut icon" type="image/png" href="favicon.png"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/jwarby/jekyll-pygments-themes@master/github.css" media="" id="highlight_theme_light"> <link rel="stylesheet" href="/assets/css/main.css"> <link rel="canonical" href="https://www.constantine-cooke.com/blog/2023/lcmm-cgh/"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/jwarby/jekyll-pygments-themes@master/native.css" media="none" id="highlight_theme_dark"> <script src="/assets/js/theme.js"></script> <script src="/assets/js/dark_mode.js"></script> </head> <body class="fixed-top-nav "> <div class="font-sans"> <header> <nav id="navbar" class="navbar navbar-light navbar-expand-sm fixed-top"> <div class="container"> <a class="navbar-brand title font-weight-lighter" href="https://www.constantine-cooke.com/">Nathan <span class="font-weight-bold">Constantine-Cooke</span></a> <button class="navbar-toggler collapsed ml-auto" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation"> <span class="sr-only">Toggle navigation</span> <span class="icon-bar top-bar"></span> <span class="icon-bar middle-bar"></span> <span class="icon-bar bottom-bar"></span> </button> <div class="collapse navbar-collapse text-right" id="navbarNav"> <ul class="navbar-nav ml-auto flex-nowrap"> <li class="nav-item "> <a class="nav-link" href="/">About</a> </li> <li class="nav-item active"> <a class="nav-link" href="/blog/">Blog<span class="sr-only">(current)</span></a> </li> <li class="nav-item "> <a class="nav-link" href="/projects/">Projects</a> </li> <li class="nav-item "> <a class="nav-link" href="/repositories/">Repositories</a> </li> <li class="nav-item "> <a class="nav-link" href="/publications/">Publications</a> </li> <li class="nav-item "> <a class="nav-link" href="/teaching/">Teaching</a> </li> <li class="nav-item "> <a class="nav-link" href="/contact/">Contact</a> </li> <li class="nav-item "> <a class="nav-link" href="/cv/">CV</a> </li> <li class="toggle-container"> <button id="light-toggle" title="Change theme"> <i class="fas fa-moon"></i> <i class="fas fa-sun"></i> </button> </li> </ul> </div> </div> </nav> <progress id="progress" value="0"> <div class="progress-container"> <span class="progress-bar"></span> </div> </progress> </header> <div class="container mt-5"> <script async type="text/javascript">window.MathJax={tex:{tags:"ams"}};</script> <script async type="text/javascript" id="MathJax-script" src="https://cdn.jsdelivr.net/npm/mathjax@3.2.0/es5/tex-mml-chtml.js"></script> <script async src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script> <div class="post"> <header class="post-header"> <h1 class="post-title text-3xl">Are There Groups of Crohn's Disease Patients with Similar Faecal Calprotectin Patterns Over Time?</h1> <p class="post-meta">April 6, 2023</p> <p class="post-tags"> <a href="/blog/2023"> <i class="fas fa-calendar fa-sm"></i> 2023 </a>   ·   <a href="/blog/tag/calprotectin"> <i class="fas fa-hashtag fa-sm"></i> calprotectin</a>   <a href="/blog/tag/crohn-s-disease"> <i class="fas fa-hashtag fa-sm"></i> crohn's-disease</a>     ·   <a href="/blog/category/phd"> <i class="fas fa-tag fa-sm"></i> PhD</a>   </p> </header> <article class="post-content"> <figure> <picture> <source class="responsive-img-srcset" media="(max-width: 480px)" srcset="/assets/img/fcal-800.webp-480.webp"></source> <source class="responsive-img-srcset" media="(max-width: 800px)" srcset="/assets/img/fcal-800.webp-800.webp"></source> <source class="responsive-img-srcset" media="(max-width: 1400px)" srcset="/assets/img/fcal-800.webp-1400.webp"></source> <img src="/assets/img/fcal-800.webp" class="img-fluid rounded z-depth-1" width="auto" height="auto" data-zoomable="" onerror="this.onerror=null; $('.responsive-img-srcset').remove();"> </picture> </figure> <p><br> People with Crohn’s disease are likely to be very familiar with faecal calprotectin kits; these tests use a stool sample to determine the amount of gastrointestinal inflammation a person has. Gastroenterologists often use the results from these kits to assist with determining how active a person’s Crohn’s disease is without needing that person needing to undergo a colonoscopy.</p> <p>We know it is crucial faecal calprotectin is kept low early after diagnosis to improve the likelihood a Crohn’s disease patient is going to have a good outcome. My colleagues at the University of Edinburgh and NHS Lothian have previously shown having a calprotectin below \(250 \; (\mu g/g)\) a year after diagnosis reduces the likelihood of the disease worsening and patients being hospitalised or requiring surgery <a class="citation" href="#Plevris2021">(Plevris et al., 2021)</a>. However, this previous work did not consider calprotectin as a measurement which changes continuously over time and instead ony considered two measurements for each person measured a year apart.</p> <p>We believed that across people with Crohn’s disease, there were likely common patterns of faecal calprotectin over time. To the best of our knowledge, no previous research had attempted to determine if we can group people with Crohn’s disease with other Crohn’s disease patients with similar calprotectin over time. Recently, colleagues and I have attempted to determine how many groups with their own shared calprotectin patterns can be reliably found, what these patterns look like, and if being in one of these groups are potentially affected by the data known at diagnosis <a class="citation" href="#Constantine_Cooke_2023">(Constantine-Cooke et al., 2023)</a>.</p> <p>For our study, we considered the calprotectin of 356 people with Crohn’s disease and followed them from diagnosis for five years. We have used highly flexible statistical models, known as latent class mixed models with natural cubic splines, to determine the number of groups with distinct calprotectin patterns and their appearance.</p> <p>We found four distinct groups which are presented below and largely reflect what is seen by gastroenterologists in clinics. Three of the groups can be broadly described as having overall decreasing calprotectin over time with the fourth group (cluster 2) having consistently high calprotectin. It is highly likely there are patients in this latter group who would have benefitted from receiving more advanced therapies sooner and also patients who would have always had aggressive disease regardless of the treatment they received. We are interested in determining which patients this is the case for in the future. <br><br></p> <figure> <picture> <source class="responsive-img-srcset" media="(max-width: 480px)" srcset="/assets/img/traj-800.webp-480.webp"></source> <source class="responsive-img-srcset" media="(max-width: 800px)" srcset="/assets/img/traj-800.webp-800.webp"></source> <source class="responsive-img-srcset" media="(max-width: 1400px)" srcset="/assets/img/traj-800.webp-1400.webp"></source> <img src="/assets/img/traj-800.webp" class="img-fluid rounded z-depth-1" width="auto" height="auto" data-zoomable="" onerror="this.onerror=null; $('.responsive-img-srcset').remove();"> </picture> </figure> <p><br></p> <p class="text-red-400"> The four distinct calprotectin profiles we found. The gray lines are the calprotectin measurements for each subject deemed to have a similar profile to the red curve. </p> <p>Of the data which are typically available at diagnosis, only smoking status and the presence of upper gastrointestinal inflammation were found to be significantly associated with which group a patient was assigned to. Smokers were more likely to be assigned to class 1 or 2 whilst people with upper gastrointestinal disease were less likely to be assigned to class 1. Whilst smokers being assigned to class 2 makes sense as smoking is highly associated with worse disease outcomes in Crohn’s disease, we do not fully understand the association we found between smoking and class 1. However, this may be due to smokers in class 1 giving up smoking after being diagnosed. Unfortunately, we do not have data for whether patients gave up smoking, and this is simply a theory.</p> <p>We found early biologic treatment being very highly associated with class membership with those in class 2 being less likely to receive early biologic treatment than the other groups. However, We were unable to accurately predict class membership using all variables available at diagnosis and data science techniques (random forest and multinomial logistic regression).</p> <p>Overall, we have shown latent class mixed models are an excellent tool for finding subgroups of people with Crohn’s disease with shared calprotectin profiles and determining these profiles in a data-driven manner (rather than asking patients which diagram shown to them best described their disease).</p> <p>We are currently working on expanding this work to include all ulcerative colitis and Crohn’s disease patients treated by the Edinburgh IBD Unit and model both CRP and calprotectin.</p> <p>Our long-term goal is to develop a tool which will predict a patient’s risk of surgery, hospitalisation, or worsening disease based on symptoms, calprotectin, and other measures which will then update as additional measurements are taken. This could then help clinicians when making decisions such as which treatment plan to place a patient on and how closely a patient should be monitored.</p> <hr> <p><br></p> <p class="text-2xl">References</p> <p><br></p> <ol class="bibliography"> <li> <div class="row"> <div class="col-sm-2 abbr"></div> <div id="Plevris2021" class="col-sm-8"> <div class="title">Normalization of fecal calprotectin within 12 months of diagnosis is associated with reduced risk of disease progression in patients with Crohn’s disease</div> <div class="author">Nikolas Plevris, James Fulforth, Mathew Lyons, Spyros I. Siakavellas, Philip W. Jenkinson, Cher S. Chuah, Laura Lucaciu, Rebecca J. Pattenden, Ian D. Arnott, Gareth-Rhys Jones, and <a href="https://charlielees.com" rel="external nofollow noopener" target="_blank">Charlie W. Lees</a> </div> <div class="periodical"> <em>Clinical Gastroenterology and Hepatology</em> Sep 2021 </div> <div class="links"> </div> </div> </div> </li> <li> <div class="row"> <div class="col-sm-2 abbr"></div> <div id="Constantine_Cooke_2023" class="col-sm-8"> <div class="title">Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn’s Disease</div> <div class="author"> <em>Nathan Constantine-Cooke</em>, Karla Monterrubio-Gómez, Nikolas Plevris, Lauranne A.A.P. Derikx, Beatriz Gros, Gareth-Rhys Jones, Riccardo E. Marioni, <a href="https://charlielees.com" rel="external nofollow noopener" target="_blank">Charlie W. Lees</a>, and <a href="https://vallejosgroup.github.io" rel="external nofollow noopener" target="_blank">Catalina A. Vallejos</a> </div> <div class="periodical"> <em>Clinical Gastroenterology and Hepatology</em> Mar 2023 </div> <div class="links"> </div> </div> </div> </li> </ol> </article> </div> </div> <footer class="fixed-bottom"> <div class="container mt-0"> © Copyright 2026 Nathan Constantine-Cooke. </div> </footer> <script defer src="https://cdn.jsdelivr.net/npm/jquery@3.6.0/dist/jquery.min.js" integrity="sha256-/xUj+3OJU5yExlq6GSYGSHk7tPXikynS7ogEvDej/m4=" crossorigin="anonymous"></script> <script defer src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.1/dist/js/bootstrap.bundle.min.js" integrity="sha256-fgLAgv7fyCGopR/gBNq2iW3ZKIdqIcyshnUULC4vex8=" crossorigin="anonymous"></script> <script defer src="https://cdn.jsdelivr.net/npm/mdbootstrap@4.20.0/js/mdb.min.js" integrity="sha256-NdbiivsvWt7VYCt6hYNT3h/th9vSTL4EDWeGs5SN3DA=" crossorigin="anonymous"></script> <script defer src="https://cdn.jsdelivr.net/npm/masonry-layout@4.2.2/dist/masonry.pkgd.min.js" integrity="sha256-Nn1q/fx0H7SNLZMQ5Hw5JLaTRZp0yILA/FRexe19VdI=" crossorigin="anonymous"></script> <script defer src="https://cdn.jsdelivr.net/npm/imagesloaded@4/imagesloaded.pkgd.min.js"></script> <script defer src="/assets/js/masonry.js" type="text/javascript"></script> <script async src="https://cdn.jsdelivr.net/npm/medium-zoom@1.0.6/dist/medium-zoom.min.js" integrity="sha256-EdPgYcPk/IIrw7FYeuJQexva49pVRZNmt3LculEr7zM=" crossorigin="anonymous"></script> <script async src="/assets/js/zoom.js"></script> <script async src="/assets/js/common.js"></script> <script async type="text/javascript">window.MathJax={tex:{tags:"ams"}};</script> <script async type="text/javascript" id="MathJax-script" src="https://cdn.jsdelivr.net/npm/mathjax@3.2.0/es5/tex-mml-chtml.js"></script> <script async src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script> <script async src="https://www.googletagmanager.com/gtag/js?id=UA-221003730-1"></script> <script>function gtag(){window.dataLayer.push(arguments)}window.dataLayer=window.dataLayer||[],gtag("js",new Date),gtag("config","UA-221003730-1");</script> <script type="text/javascript">function progressBarSetup(){"max"in document.createElement("progress")?(initializeProgressElement(),$(document).on("scroll",function(){progressBar.attr({value:getCurrentScrollPosition()})}),$(window).on("resize",initializeProgressElement)):(resizeProgressBar(),$(document).on("scroll",resizeProgressBar),$(window).on("resize",resizeProgressBar))}function getCurrentScrollPosition(){return $(window).scrollTop()}function initializeProgressElement(){let e=$("#navbar").outerHeight(!0);$("body").css({"padding-top":e}),$("progress-container").css({"padding-top":e}),progressBar.css({top:e}),progressBar.attr({max:getDistanceToScroll(),value:getCurrentScrollPosition()})}function getDistanceToScroll(){return $(document).height()-$(window).height()}function resizeProgressBar(){progressBar.css({width:getWidthPercentage()+"%"})}function getWidthPercentage(){return getCurrentScrollPosition()/getDistanceToScroll()*100}const progressBar=$("#progress");window.onload=function(){setTimeout(progressBarSetup,50)};</script> </div> </body> </html>